Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
N Engl J Med. 2013 Jul 11;369(2):155-63. doi: 10.1056/NEJMoa1209165.
BACKGROUND: The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. childhood immunization schedule in 2000 has substantially reduced the incidence of vaccine-serotype invasive pneumococcal disease in young children and in unvaccinated older children and adults. By 2004, hospitalizations associated with pneumonia from any cause had also declined markedly among young children. Because of concerns about increases in disease caused by nonvaccine serotypes, we wanted to determine whether the reduction in pneumonia-related hospitalizations among young children had been sustained through 2009 and whether such hospitalizations in older age groups had also declined. METHODS: We estimated annual rates of hospitalization for pneumonia from any cause using the Nationwide Inpatient Sample database. The reason for hospitalization was classified as pneumonia if pneumonia was the first listed diagnosis or if it was listed after a first diagnosis of sepsis, meningitis, or empyema. Average annual rates of pneumonia-related hospitalizations from 1997 through 1999 (before the introduction of PCV7) and from 2007 through 2009 (well after its introduction) were used to estimate annual declines in hospitalizations due to pneumonia. RESULTS: The annual rate of hospitalization for pneumonia among children younger than 2 years of age declined by 551.1 per 100,000 children (95% confidence interval [CI], 445.1 to 657.1), which translates to 47,000 fewer hospitalizations annually than expected on the basis of the rates before PCV7 was introduced. The rate for adults 85 years of age or older declined by 1300.8 per 100,000 (95% CI, 984.0 to 1617.6), which translates to 73,000 fewer hospitalizations annually. For the three age groups of 18 to 39 years, 65 to 74 years, and 75 to 84 years, the annual rate of hospitalization for pneumonia declined by 8.4 per 100,000 (95% CI, 0.6 to 16.2), 85.3 per 100,000 (95% CI, 7.0 to 163.6), and 359.8 per 100,000 (95% CI, 199.6 to 520.0), respectively. Overall, we estimated an age-adjusted annual reduction of 54.8 per 100,000 (95% CI, 41.0 to 68.5), or 168,000 fewer hospitalizations for pneumonia annually. CONCLUSIONS: Declines in hospitalizations for childhood pneumonia were sustained during the decade after the introduction of PCV7. Substantial reductions in hospitalizations for pneumonia among adults were also observed. (Funded by the Centers for Disease Control and Prevention.).
背景:2000 年,7 价肺炎球菌结合疫苗(PCV7)被引入美国儿童免疫计划,这大大降低了小儿疫苗血清型侵袭性肺炎球菌病的发病率,以及未接种疫苗的大龄儿童和成年人的发病率。到 2004 年,因任何原因导致的肺炎住院率也明显下降。由于担心非疫苗血清型疾病的增加,我们想确定儿童肺炎相关住院率是否持续下降到 2009 年,以及大龄儿童的此类住院率是否也有所下降。
方法:我们使用全国住院患者样本数据库估计因任何原因导致的肺炎住院的年发病率。如果肺炎是第一个列出的诊断,或者它是在败血症、脑膜炎或脓胸的首次诊断后列出的,则将住院的原因归类为肺炎。2007 年至 2009 年(PCV7 推出后)的平均年度肺炎相关住院率用于估计因肺炎导致的住院率的年度下降。
结果:2 岁以下儿童肺炎的年住院率下降了 551.1/10 万儿童(95%置信区间[CI]:445.1-657.1),这意味着每年比 PCV7 推出前的预期住院人数减少了 4.7 万。85 岁及以上成年人的肺炎年住院率下降了 1300.8/10 万(95%CI:984.0-1617.6),这意味着每年减少了 7.3 万例住院。对于 18-39 岁、65-74 岁和 75-84 岁三个年龄组,肺炎的年住院率分别下降了 8.4/10 万(95%CI:0.6-16.2)、85.3/10 万(95%CI:7.0-163.6)和 359.8/10 万(95%CI:199.6-520.0)。总的来说,我们估计年龄调整后的年发病率下降了 54.8/10 万(95%CI:41.0-68.5),即每年因肺炎住院的人数减少了 16.8 万。
结论:PCV7 推出后的十年间,儿童肺炎住院率下降趋势持续。成年人因肺炎住院率也大幅下降。(由疾病控制和预防中心资助)。
N Engl J Med. 2013-7-11
Bull World Health Organ. 2012-12-11
MMWR Morb Mortal Wkly Rep. 2009-1-16
Antimicrob Agents Chemother. 2025-9-3
Chronic Dis Transl Med. 2023-5-8
Pediatr Infect Dis J. 2012-3
Lancet. 2011-4-12
Clin Infect Dis. 2011-5